Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO for MRD in Acute Myeloid Leukemia
NCT03737955Phase 2Recruiting
- Sponsor
- University of Washington
- Start
- Nov 2018
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by University of Washington. Primary endpoint: Clinical response rate at 70 days. Started Nov 2018; status: recruiting.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03737955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737955.